Participant Basic Agreement (PBA) Opportunity - Threat Agnostic Host-Directed Therapeutics

SOL #: W911SR-26-R-HEALSpecial Notice

Overview

Buyer

DEPT OF DEFENSE

Dept Of The Army

W6QK ACC-APG

ABERDEEN PROVING GROU, MD, 21010-5424, United States

Place of Performance

Place of performance not available

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

National Defense R&D Services; Department Of Defense Military; Experimental Development (AC13)

Set Aside

No set aside specified

Original Source

https://sam.gov/opp/502f210118c74230b3b6f1e06ab4dec8/view

Timeline

Posted

Apr 23, 2026

Last Updated

Apr 23, 2026

Qualification Details

Fit reasons

NAICS alignment with historical contract wins in similar service areas.
Scope strongly matches core technical capabilities and delivery model.

Risks

Past performance thresholds may require one additional teaming partner.
Potential clarification needed on staffing minimums before bid/no-bid.

Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Department of the Army, through the Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND), has issued a Special Notice for the HEALER portfolio. This initiative seeks to develop threat-agnostic, host-directed therapeutics to enhance the body's ability to withstand, mitigate, and recover from CBRN threats. The program focuses on dual-use therapeutics, aligning national security with commercial market incentives. Participation will be under a Participant Basic Agreement (PBA).

Scope of Work

The HEALER portfolio aims to create a new generation of therapeutics that enable the 'Host' to recover from physiological impacts and maintain operational effectiveness. The program focuses on delivering medical countermeasures that provide layered physiological protection by targeting one or more of the following critical host systems:

Neurological Protection
Respiratory Stabilization
Immune Modulation
Hematologic & Vascular Function
Cellular Stress & Repair Pathways

Call for Collaborators

This opportunity invites the full spectrum of drug development organizations:

Therapeutic Development Collaborators: Developers of host-directed therapeutic candidates.
Drug Development Support Collaborators: Organizations specializing in contract research, development, and manufacturing (CROs/CDMOs), preclinical testing, clinical trial execution, cGMP manufacturing, regulatory submissions, and advanced modeling.

Submission Requirements

Interested entities must submit a white paper (not to exceed five pages, excluding cover page) addressing specific areas. Companies should also state their willingness to team or collaborate with other PBA holders.

For Therapeutic Development Collaborators: Submissions require a comprehensive overview including product description, efficacy data, regulatory & clinical status, manufacturing capabilities, and company profile.
For Drug Development Support Collaborators: Submissions should summarize core capabilities, relevant experience (biologics/small molecules, FDA regulatory), available infrastructure, and technology.

Contract & Timeline

Type: Special Notice, leading to Participant Basic Agreements (PBA).
Authority: Projects may be awarded under 10 U.S.C §4021, §4022, and §4023, which are not subject to the Competition in Contracting Act.
Set-Aside: None specified.
Published: April 23, 2026.
Response Due: Not specified in this notice.
Notes: Prospective awardees must be registered in SAM.gov prior to submitting an invoice and through final payment.